JP2024544523A5 - - Google Patents

Info

Publication number
JP2024544523A5
JP2024544523A5 JP2024527460A JP2024527460A JP2024544523A5 JP 2024544523 A5 JP2024544523 A5 JP 2024544523A5 JP 2024527460 A JP2024527460 A JP 2024527460A JP 2024527460 A JP2024527460 A JP 2024527460A JP 2024544523 A5 JP2024544523 A5 JP 2024544523A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
stable aqueous
aqueous pharmaceutical
composition according
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544523A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/079535 external-priority patent/WO2023086817A1/en
Publication of JP2024544523A publication Critical patent/JP2024544523A/ja
Publication of JP2024544523A5 publication Critical patent/JP2024544523A5/ja
Pending legal-status Critical Current

Links

JP2024527460A 2021-11-10 2022-11-09 二重特異性bcma/cd3抗体を含む安定な製剤 Pending JP2024544523A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163277885P 2021-11-10 2021-11-10
US63/277,885 2021-11-10
PCT/US2022/079535 WO2023086817A1 (en) 2021-11-10 2022-11-09 Stable formulations comprising a bispecific bcma/cd3 antibody

Publications (2)

Publication Number Publication Date
JP2024544523A JP2024544523A (ja) 2024-12-03
JP2024544523A5 true JP2024544523A5 (cg-RX-API-DMAC7.html) 2025-11-17

Family

ID=86336796

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527460A Pending JP2024544523A (ja) 2021-11-10 2022-11-09 二重特異性bcma/cd3抗体を含む安定な製剤

Country Status (11)

Country Link
US (1) US20230279136A1 (cg-RX-API-DMAC7.html)
EP (1) EP4430082A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024544523A (cg-RX-API-DMAC7.html)
KR (1) KR20240099432A (cg-RX-API-DMAC7.html)
CN (1) CN118251417A (cg-RX-API-DMAC7.html)
AU (1) AU2022383848A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238152A1 (cg-RX-API-DMAC7.html)
IL (1) IL312700A (cg-RX-API-DMAC7.html)
MX (1) MX2024005727A (cg-RX-API-DMAC7.html)
TW (1) TW202328209A (cg-RX-API-DMAC7.html)
WO (1) WO2023086817A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4426437A4 (en) 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES
WO2024044545A1 (en) * 2022-08-23 2024-02-29 Janssen Biotech, Inc. Approved products for the treatment of multiple myeloma
WO2024044548A1 (en) * 2022-08-23 2024-02-29 Janssen Biotech, Inc. Teclistamab for the treatment of multiple myeloma
CN121358776A (zh) * 2023-05-09 2026-01-16 詹森生物科技公司 包含高浓度的双特异性bcma/cd3抗体的药物组合物
TW202517293A (zh) * 2023-07-07 2025-05-01 美商再生元醫藥公司 含有抗bcmax抗cd3雙特異性抗體之穩定化配製物
KR20260057078A (ko) * 2023-08-18 2026-04-27 브리스톨-마이어스 스큅 컴퍼니 Bcma 및 cd3에 결합하는 항체를 포함하는 조성물 및 치료 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE230277T1 (de) * 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
TWI811023B (zh) * 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
JOP20170017B1 (ar) * 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
US20200308296A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
AR118720A1 (es) * 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
CN116249548A (zh) * 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法

Similar Documents

Publication Publication Date Title
JP2023540025A5 (cg-RX-API-DMAC7.html)
JP2024016177A5 (cg-RX-API-DMAC7.html)
JP2022532927A5 (cg-RX-API-DMAC7.html)
FI4249512T3 (fi) Stabiili vasta-aineformulaatio
JP2024514344A5 (cg-RX-API-DMAC7.html)
WO2020094122A1 (zh) 一种TGF-β受体融合蛋白药物组合物及其用途
JP2020518598A5 (cg-RX-API-DMAC7.html)
CN115666649B (zh) 一种新型冠状病毒抗体的药物组合物及其用途
RU2006120950A (ru) Антитело к cd40: препарат и способы
JP2024531151A5 (cg-RX-API-DMAC7.html)
JP2016534052A5 (cg-RX-API-DMAC7.html)
US20140271653A1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
JP2024506940A5 (cg-RX-API-DMAC7.html)
JP2024515968A5 (cg-RX-API-DMAC7.html)
AR124067A2 (es) Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met
AR126614A1 (es) Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma
JP2025500784A5 (cg-RX-API-DMAC7.html)
JP2023502398A5 (cg-RX-API-DMAC7.html)
CN117159703B (zh) 含抗lag-3抗体的药物组合物及其用途
JP2023535433A (ja) Pd-l1/lag-3二重特異性抗体製剤およびその調製方法ならびに使用
KR101581517B1 (ko) Tgf-알파 및 에피레굴린에 결합하는 항체
RU2020111574A (ru) Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом
AR130130A1 (es) Proteínas de unión al receptor de transferrina para tratar tumores cerebrales
RU2025126086A (ru) Композиции, содержащие биспецифическое антитело к gprc5d/cd3
WO2023134787A3 (zh) 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途